Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 587
- Registration Number
- NCT00003299
- Locations
- ๐บ๐ธ
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
๐บ๐ธCCOP - Carle Cancer Center, Urbana, Illinois, United States
๐บ๐ธCCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 53
- Registration Number
- NCT00003573
- Locations
- ๐บ๐ธ
Hope Children's Hospital, Oak Lawn, Illinois, United States
๐บ๐ธArizona Cancer Center, Tucson, Arizona, United States
๐บ๐ธSaint Jude Midwest Affiliate, Peoria, Illinois, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
- Conditions
- Interventions
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 31
- Registration Number
- NCT00003935
- Locations
- ๐บ๐ธ
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
๐บ๐ธUniversity of California San Diego Cancer Center, La Jolla, California, United States
๐บ๐ธMarlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005631
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2012-07-16
- Target Recruit Count
- 106
- Registration Number
- NCT00006122
- Locations
- ๐ซ๐ท
Hotel Dieu de Paris, Paris, France
๐ง๐ชA.Z. St. Jan, Brugge, Belgium
๐ฆ๐นInnsbruck Universitaetsklinik, Innsbruck, Austria
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00003632
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Registration Number
- NCT00002531
- Locations
- ๐ฉ๐ช
Klinikum der J.W. Goethe Universitaet, Frankfurt, Germany
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Hannover Medical School
- Registration Number
- NCT00002532
- Locations
- ๐ฉ๐ช
Medizinische Hochschule Hannover, Hannover, Germany
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 744
- Registration Number
- NCT00002868
- Locations
- ๐ฌ๐ง
Royal Infirmary, Glasgow, Scotland, United Kingdom
๐บ๐ธHackensack University Medical Center, Hackensack, New Jersey, United States
๐บ๐ธRiverview Medical Center - Booker Cancer Center, Red Bank, New Jersey, United States
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 44
- Registration Number
- NCT00007852
- Locations
- ๐บ๐ธ
University of Nebraska Medical Center, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.